SCHEMBL30765718

SCHEMBL30765718

Cc1ncc(N)c(=O)n1CC(=O)NCc1cc2cnccc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.45
F2 P00734 9/20 0.41
PRSS1 P07477 5/20 0.41
NTRK3 Q16288 1/20 0.40
MTNR1B P49286 1/20 0.40
CMA1 P23946 3/20 0.38
CTRC Q99895 3/20 0.38
IDE P14735 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
MASP2 O00187 1/20 0.37
EGFR P00533 1/20 0.36
ERBB2 P04626 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765506 0.91 NTRK1 (0.51) NTRK1NTRK3CMA1CTRC
SCHEMBL30765874 0.86 NTRK1 (0.41) NTRK1F2PRSS1NTRK3MTNR1B
SCHEMBL30765520 0.79 NTRK1 (0.41) NTRK1F2PRSS1NTRK3MTNR1B
SCHEMBL31558522 0.78 MTNR1B (0.45) NTRK1MTNR1BIDEPPARGPPARA
SCHEMBL32680681 0.74 ALDH1A1 (0.50) NTRK1MTNR1BIDEKMT2APPARG
SCHEMBL31750757 0.74 PPARG (0.42) NTRK1MTNR1BIDEPPARGPPARA
SCHEMBL30765582 0.74 KDM4C (0.42) NTRK1NTRK3MTNR1B
SCHEMBL30765810 0.73 CTRC (0.47) NTRK1NTRK3CMA1CTRC
SCHEMBL30765640 0.71 NTRK1 (0.45) NTRK1NTRK3CMA1CTRC
SCHEMBL30765549 0.71 PPARG (0.44) IDEKMT2APPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed